DDrare: Database of Drug Development for Rare Diseases

Searched query = "Prader-Willi syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = 1.2 mg ZGN-440 for injectable suspension; 1.8 mg ZGN-440 for injectable suspension; ACOMPLIA 20 mg film-coated tablets; ACTH; AZP-531; Acetylcysteine; Acomplia; Air; Anastrozole; B. lactis B94; Beloranib; Byetta; CBDV; CBDV Compound; Cannabidiol; Cannabidiol Oral Solution; Carbetocin; Chloride; Choline; Coenzyme Q10; D.3.2 Product code where applicable13:; DCCR; DIAZOXIDE CHOLINE; Diazoxide; Diazoxide choline; Diazoxide choline controlled-release tablet; EU/1/06/362/003: 5µg (1 pen); Eutropin; Exenatide; FE 992097; Fluimucil; Fluimucil (acetylcysteine); GENOTONORM; GENOTROPIN (Somatropin) is a growth hormone treatment. It is an exact copy of the natural growth hormone that our bodies make. The main difference is that GENOTROPIN is man-made.; GLWL-01; Genotonorm; Genotonorm Miniquick 0,2 mg; Genotropin; Growth hormone; Growth hormone (Genotonorm® or Omnitrope®); Guanfacine; Guanfacine extended release (GXR); Human growth hormone; Humatrope 6 mg/12 mg/24 mg injektiokuiva-aine ja liuotin, liuosta varten; INN Not yet proposed; Intranasal Oxytocin (IN-OXT); Intranasal carbetocin Dose 1; Intranasal carbetocin Dose 2; Intranasal oxytocin; LIRAGLUTIDE; Liraglutide; Livoletide; METOPROLOL SUCCINATE; Medical Air vs Oxygen; Medical air; Metoprolol; Metoprololsuccinat Orion 25mg; Metoprololsuccinat ”Orion” 25mg; Metyrapone; Norditropin SimpleXx; Nutropin AQ; OMNITROPE; OT; OXYTOCIN; Octreotide; Omnitrope; Other: Control; Other: Low dose (1 mcg) ACTH stimulation test; Other: Overnight metyrapone test; Oxygen; Oxytocin; Oxytocin (OXT) continuous; Physiological serum (Sodium chloride); Pitolisant; Pitolisant oral tablets; Probiotic; Procedure: DEXA, blood tests, H.G.P.O, osseous age.; Procedure: biopsy; R05CB01; RECOMBINANT HUMAN GROWTH HORMON; RECOMBINANT HUMAN GROWTH HORMONE; RM-493; Recombinant Human Growth Hormone (rhGH) Injection; Recombinant Somatropin; Recombinant human growth hormone; RhGH; Rimonabant; SOMATROPIN; Sandostatin LAR; Saxenda; Sodium chloride; Somatropin; Subcutaneous Beloranib in Suspension; Syntocinon; Syntocinon nasal spray; Syntocinon®/- Spray; TESOFENSINE; Tesofensine; Tesofensine/Metoprolol; Topiramate; ZGN-440; ZGN-440 for Injectable Suspension; ZGN-440 sterile diluent; [AZP-531]

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2014-004415-37-NL (EUCTR)	07/03/2016	17/08/2015	Effect of liraglutide for weight management in children with Prader-Willi Syndrome	Effect of liraglutide for weight management in paediatric subjects with Prader-Willi Syndrome. A randomised, placebo controlled, parallel group, multi-centre, multinational trial with a 16-week double-blind period and 36-week open-label period	Obesity(Prader-Willi syndrome) MedDRA version: 18.1;Level: PT;Classification code 10029883;Term: Obesity;System Organ Class: 10027433 - Metabolism and nutrition disorders;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]	Trade Name: Saxenda INN or Proposed INN: LIRAGLUTIDE	Novo Nordisk A/S	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	60		United States;European Union;Canada;Turkey;Australia;Netherlands;New Zealand
2	EUCTR2014-004415-37-IT (EUCTR)	10/11/2015	29/07/2015	Effect of liraglutide for weight management in children with Prader-Willi Syndrome	Effect of liraglutide for weight management in paediatric subjects with Prader-Willi Syndrome. A randomised, placebo controlled, parallel group, multi-centre, multinational trial with a 16-week double-blind period and 36-week open-label period	Obesity(Prader-Willi syndrome) MedDRA version: 18.0;Level: PT;Classification code 10029883;Term: Obesity;System Organ Class: 10027433 - Metabolism and nutrition disorders;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]	Trade Name: Saxenda INN or Proposed INN: LIRAGLUTIDE	Novo Nordisk A/S	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	60	Phase 3	Turkey;Australia;Netherlands;New Zealand;Italy;France;United States;European Union;Canada
3	NCT02527200 (ClinicalTrials.gov)	November 9, 2015	17/8/2015	Effect of Liraglutide for Weight Management in Paediatric Subjects With Prader-Willi Syndrome	Effect of Liraglutide for Weight Management in Paediatric Subjects With Prader-Willi Syndrome.	Metabolism and Nutrition Disorder;Obesity	Drug: liraglutide;Drug: placebo	Novo Nordisk A/S	NULL	Completed	6 Years	18 Years	All	56	Phase 3	United States;Australia;Canada;France;Italy;Netherlands;New Zealand;Turkey
4	NCT01542242 (ClinicalTrials.gov)	February 2012	21/2/2012	Liraglutide Use in Prader-Willi Syndrome		Diabetes Mellitus Type 2;Prader Willi Syndrome	Drug: Liraglutide	Vancouver General Hospital	Novo Nordisk A/S	Terminated	19 Years	N/A	Male	1	Phase 4	Canada
5	EUCTR2014-004415-37-FR (EUCTR)		04/08/2015	Effect of liraglutide for weight management in children with Prader-Willi Syndrome	Effect of liraglutide for weight management in paediatric subjects with Prader-Willi Syndrome. A randomised, placebo controlled, parallel group, multi-centre, multinational trial with a 16-week double-blind period and 36-week open-label period	Obesity(Prader-Willi syndrome) MedDRA version: 18.0;Level: PT;Classification code 10029883;Term: Obesity;System Organ Class: 10027433 - Metabolism and nutrition disorders;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]	Trade Name: Saxenda INN or Proposed INN: LIRAGLUTIDE	Novo Nordisk A/S	NULL	NA			Female: yes Male: yes	60	Phase 3	United States;France;European Union;Canada;Turkey;Australia;Netherlands;Italy;New Zealand

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

EUCTR2014-004415-37-NL
(EUCTR)

07/03/2016

17/08/2015

Effect of liraglutide for weight management in children with Prader-Willi Syndrome

Effect of liraglutide for weight management in paediatric subjects with Prader-Willi Syndrome. A randomised, placebo controlled, parallel group, multi-centre, multinational trial with a 16-week double-blind period and 36-week open-label period

Obesity(Prader-Willi syndrome)
MedDRA version: 18.1;Level: PT;Classification code 10029883;Term: Obesity;System Organ Class: 10027433 - Metabolism and nutrition disorders;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]

Trade Name: Saxenda
INN or Proposed INN: LIRAGLUTIDE

Novo Nordisk A/S

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

United States;European Union;Canada;Turkey;Australia;Netherlands;New Zealand

EUCTR2014-004415-37-IT
(EUCTR)

10/11/2015

29/07/2015

Effect of liraglutide for weight management in children with Prader-Willi Syndrome

Obesity(Prader-Willi syndrome)
MedDRA version: 18.0;Level: PT;Classification code 10029883;Term: Obesity;System Organ Class: 10027433 - Metabolism and nutrition disorders;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]

Trade Name: Saxenda
INN or Proposed INN: LIRAGLUTIDE

Novo Nordisk A/S

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

Phase 3

Turkey;Australia;Netherlands;New Zealand;Italy;France;United States;European Union;Canada

NCT02527200
(ClinicalTrials.gov)

November 9, 2015

17/8/2015

Effect of Liraglutide for Weight Management in Paediatric Subjects With Prader-Willi Syndrome

Effect of Liraglutide for Weight Management in Paediatric Subjects With Prader-Willi Syndrome.

Metabolism and Nutrition Disorder;Obesity

Drug: liraglutide;Drug: placebo

Novo Nordisk A/S

NULL

Completed

6 Years

18 Years

All

Phase 3

United States;Australia;Canada;France;Italy;Netherlands;New Zealand;Turkey

NCT01542242
(ClinicalTrials.gov)

February 2012

21/2/2012

Liraglutide Use in Prader-Willi Syndrome

Diabetes Mellitus Type 2;Prader Willi Syndrome

Drug: Liraglutide

Vancouver General Hospital

Novo Nordisk A/S

Terminated

19 Years

N/A

Male

Phase 4

Canada

EUCTR2014-004415-37-FR
(EUCTR)

04/08/2015

Effect of liraglutide for weight management in children with Prader-Willi Syndrome

Trade Name: Saxenda
INN or Proposed INN: LIRAGLUTIDE

Novo Nordisk A/S

NULL

Female: yes
Male: yes

Phase 3

United States;France;European Union;Canada;Turkey;Australia;Netherlands;Italy;New Zealand